<p>Aura Biosciences（纳斯达克代码：AURA - 获取免费报告）可能会在 2026 年 5 月 14 日星期四市场开盘前发布其 2026 年第一季度的财报。分析师预计 Aura Biosciences 本季度每股收益为（$0.40）。各方可以查看公司即将发布的 2026 年第一季度财报中的信息，以获取关于定于 2026 年 5 月 15 日星期五上午 9:30（东部时间）的电话会议的最新细节。</p>
<p>获取 <strong>Aura Biosciences</strong> 的提醒：</p>
<ul>
<li>3 只准备实现显著增长的小型股</li>
</ul>
<p>Aura Biosciences（纳斯达克代码：AURA - 获取免费报告）最近在 3 月 30 日星期一发布了其财报。公司报告本季度每股收益为（$0.37），超出市场普遍预期的（$0.43）$0.06。分析师平均预计 Aura Biosciences 本财年的每股收益为-$2，下一财年的每股收益也为-$2。</p>
<h2>Aura Biosciences 股票上涨 2.4%</h2>
<p>纳斯达克代码：AURA 的股票在星期五以$8.40 开盘。该公司的 50 日移动平均价格为$6.66，200 日移动平均价格为$6.05。该股票的市值为 5.3928 亿美元，市盈率为-4.69，贝塔值为 0.37。Aura Biosciences 的 52 周低点为$4.34，52 周高点为$9.53。</p>
<h2>内部人士买卖</h2>
<p>在其他 Aura Biosciences 的新闻中，内部人士 Los Pinos Elisabet De 在 2 月 17 日星期二出售了 47,648 股公司的股票，交易平均价格为$5.06，总交易额为$241,098.88。出售后，该内部人士持有公司的 409,815 股股票，估值约为$2,073,663.90。这笔交易代表其持股减少了 10.42%。该交易已在提交给证券交易委员会的文件中披露，您可以通过此链接访问。此外，内部人士 Conor Kilroy 在 2 月 17 日星期二出售了 12,079 股公司的股票，交易平均价格为$5.05，总交易额为$60,998.95。出售后，该内部人士直接持有 167,234 股公司的股票，估值约为$844,531.70。该交易使其持股减少了 6.74%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 116,305 股公司股票，价值$611,230。目前，内部人士持有该股票的 6.30%。</p>
<h2>Aura Biosciences 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对 AURA 的持股。Dynamic Technology Lab Private Ltd 在第一季度收购了 Aura Biosciences 的新股份，价值约为$137,000。Invesco Ltd.在第二季度收购了 Aura Biosciences 的新股份，价值约为$76,000。Nantahala Capital Management LLC 在第二季度将其在 Aura Biosciences 的持股增加了 67.1%。Nantahala Capital Management LLC 现在拥有 2,117,697 股公司的股票，价值$13,257,000，在上个季度又购买了 850,000 股。Ameriprise Financial Inc.在第二季度将其在 Aura Biosciences 的持股增加了 31.1%。Ameriprise Financial Inc.现在拥有 84,558 股公司的股票，价值$529,000，在上个季度又购买了 20,065 股。最后，Bridgeway Capital Management LLC 在第二季度收购了 Aura Biosciences 的新股份，价值约为$102,000。机构投资者和对冲基金目前持有公司 96.75% 的股票。</p>
<h2>分析师评级变动</h2>
<p>AURA 已成为几份分析师报告的主题。Weiss Ratings 在 3 月 27 日星期五的报告中重申了对 Aura Biosciences 股票的 “卖出（d-）” 评级。HC Wainwright 在 4 月 29 日星期三的报告中将 Aura Biosciences 的目标价格从$22.00 上调至$24.00，并给予公司 “买入” 评级。最后，Wall Street Zen 在 4 月 4 日星期六的报告中将 Aura Biosciences 的评级从 “卖出” 上调至 “持有”。三位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价格为$21.50。</p>
<p><strong>阅读我们对 Aura Biosciences 的最新股票分析</strong></p>
<h2>Aura Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Aura Biosciences 是一家临床阶段的生物制药公司，专注于开发新型病毒样颗粒（VLP）疗法以治疗癌症。通过将专有的 VLP 技术与光激活染料相结合，Aura 旨在提供高度选择性的光动力疗法，针对并摧毁肿瘤细胞，同时保护健康组织。该公司的平台旨在解决眼科和非眼科环境中的实体肿瘤，利用近红外光的精确激活来诱导局部肿瘤细胞凋亡并刺激抗肿瘤免疫反应。</p>
<p>主要产品候选药物 AU-011 正在对患有脉络膜黑色素瘤的患者进行评估，这是一种罕见但可能危及视力的眼癌。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Aura Biosciences 更具吸引力</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Aura Biosciences 吗？</h2>
<p>在考虑 Aura Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aura Biosciences 并不在名单上。</p>
<p>虽然 Aura Biosciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AURA

<p>Aura Biosciences（纳斯达克代码：AURA）定于 5 月 14 日发布 2026 年第一季度财报，分析师预计每股亏损 0.40 美元。该公司此前报告每股亏损 0.37 美元，超出预期。当前股价为 8.40 美元，市值为 5.3928 亿美元。内部交易活动中出现了大量股票出售，机构投资者持有 96.75% 的股份。分析师评级各异，普遍评级为 “持有”，目标价为 21.50 美元</p>

<p>Aura Biosciences (NASDAQ:AURA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Aura Biosciences to post earnings of ($0.40) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.</p>
<div class="lb-trans"><p>Aura Biosciences（纳斯达克代码：AURA - 获取免费报告）可能会在 2026 年 5 月 14 日星期四市场开盘前发布其 2026 年第一季度的财报。分析师预计 Aura Biosciences 本季度每股收益为（$0.40）。各方可以查看公司即将发布的 2026 年第一季度财报中的信息，以获取关于定于 2026 年 5 月 15 日星期五上午 9:30（东部时间）的电话会议的最新细节。</p>
</div><p>Get <strong>Aura Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aura Biosciences</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备实现显著增长的小型股</li>
</ul>
</div><p>Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Aura Biosciences（纳斯达克代码：AURA - 获取免费报告）最近在 3 月 30 日星期一发布了其财报。公司报告本季度每股收益为（$0.37），超出市场普遍预期的（$0.43）$0.06。分析师平均预计 Aura Biosciences 本财年的每股收益为-$2，下一财年的每股收益也为-$2。</p>
</div><h2>Aura Biosciences Stock Up 2.4%</h2>
<div class="lb-trans"><h2>Aura Biosciences 股票上涨 2.4%</h2>
</div><p>Shares of NASDAQ:AURA opened at $8.40 on Friday. The firm's 50 day moving average price is $6.66 and its 200 day moving average price is $6.05. The stock has a market cap of $539.28 million, a price-to-earnings ratio of -4.69 and a beta of 0.37. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $9.53.</p>
<div class="lb-trans"><p>纳斯达克代码：AURA 的股票在星期五以$8.40 开盘。该公司的 50 日移动平均价格为$6.66，200 日移动平均价格为$6.05。该股票的市值为 5.3928 亿美元，市盈率为-4.69，贝塔值为 0.37。Aura Biosciences 的 52 周低点为$4.34，52 周高点为$9.53。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Aura Biosciences news, insider Los Pinos Elisabet De sold 47,648 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $241,098.88. Following the sale, the insider owned 409,815 shares of the company's stock, valued at approximately $2,073,663.90. This trade represents a 10.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, insider Conor Kilroy sold 12,079 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $5.05, for a total transaction of $60,998.95. Following the sale, the insider directly owned 167,234 shares in the company, valued at approximately $844,531.70. The trade was a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 116,305 shares of company stock valued at $611,230 over the last three months. 6.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Aura Biosciences 的新闻中，内部人士 Los Pinos Elisabet De 在 2 月 17 日星期二出售了 47,648 股公司的股票，交易平均价格为$5.06，总交易额为$241,098.88。出售后，该内部人士持有公司的 409,815 股股票，估值约为$2,073,663.90。这笔交易代表其持股减少了 10.42%。该交易已在提交给证券交易委员会的文件中披露，您可以通过此链接访问。此外，内部人士 Conor Kilroy 在 2 月 17 日星期二出售了 12,079 股公司的股票，交易平均价格为$5.05，总交易额为$60,998.95。出售后，该内部人士直接持有 167,234 股公司的股票，估值约为$844,531.70。该交易使其持股减少了 6.74%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 116,305 股公司股票，价值$611,230。目前，内部人士持有该股票的 6.30%。</p>
</div><h2>Institutional Trading of Aura Biosciences</h2>
<div class="lb-trans"><h2>Aura Biosciences 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. Dynamic Technology Lab Private Ltd acquired a new stake in Aura Biosciences during the first quarter worth approximately $137,000. Invesco Ltd. acquired a new stake in Aura Biosciences during the second quarter worth approximately $76,000. Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after purchasing an additional 850,000 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Aura Biosciences by 31.1% during the second quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company's stock worth $529,000 after purchasing an additional 20,065 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Aura Biosciences during the second quarter worth approximately $102,000. Institutional investors and hedge funds own 96.75% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对 AURA 的持股。Dynamic Technology Lab Private Ltd 在第一季度收购了 Aura Biosciences 的新股份，价值约为$137,000。Invesco Ltd.在第二季度收购了 Aura Biosciences 的新股份，价值约为$76,000。Nantahala Capital Management LLC 在第二季度将其在 Aura Biosciences 的持股增加了 67.1%。Nantahala Capital Management LLC 现在拥有 2,117,697 股公司的股票，价值$13,257,000，在上个季度又购买了 850,000 股。Ameriprise Financial Inc.在第二季度将其在 Aura Biosciences 的持股增加了 31.1%。Ameriprise Financial Inc.现在拥有 84,558 股公司的股票，价值$529,000，在上个季度又购买了 20,065 股。最后，Bridgeway Capital Management LLC 在第二季度收购了 Aura Biosciences 的新股份，价值约为$102,000。机构投资者和对冲基金目前持有公司 96.75% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>AURA has been the topic of several analyst reports. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Aura Biosciences in a report on Friday, March 27th. HC Wainwright raised their target price on shares of Aura Biosciences from $22.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Aura Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 4th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $21.50.</p>
<div class="lb-trans"><p>AURA 已成为几份分析师报告的主题。Weiss Ratings 在 3 月 27 日星期五的报告中重申了对 Aura Biosciences 股票的 “卖出（d-）” 评级。HC Wainwright 在 4 月 29 日星期三的报告中将 Aura Biosciences 的目标价格从$22.00 上调至$24.00，并给予公司 “买入” 评级。最后，Wall Street Zen 在 4 月 4 日星期六的报告中将 Aura Biosciences 的评级从 “卖出” 上调至 “持有”。三位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价格为$21.50。</p>
</div><p><strong>Read Our Latest Stock Analysis on Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Aura Biosciences 的最新股票分析</strong></p>
</div><h2>Aura Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Aura Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.</p>
<div class="lb-trans"><p>Aura Biosciences 是一家临床阶段的生物制药公司，专注于开发新型病毒样颗粒（VLP）疗法以治疗癌症。通过将专有的 VLP 技术与光激活染料相结合，Aura 旨在提供高度选择性的光动力疗法，针对并摧毁肿瘤细胞，同时保护健康组织。该公司的平台旨在解决眼科和非眼科环境中的实体肿瘤，利用近红外光的精确激活来诱导局部肿瘤细胞凋亡并刺激抗肿瘤免疫反应。</p>
</div><p>The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.</p>
<div class="lb-trans"><p>主要产品候选药物 AU-011 正在对患有脉络膜黑色素瘤的患者进行评估，这是一种罕见但可能危及视力的眼癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Aura Biosciences</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Aura Biosciences 更具吸引力</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aura Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Aura Biosciences 吗？</h2>
</div><p>Before you consider Aura Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aura Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aura Biosciences 并不在名单上。</p>
</div><p>While Aura Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aura Biosciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aura Biosciences (AURA) 将在周四公布财报